Initial Public Offerings

We believe IPO's are critical to the success of emerging growth companies. Ours is a new IPO solution.

From 1990 to 1996, more than 1,200 U.S. venture-backed companies went public on U.S. exchanges. From 2004 to 2015, only 324 did so.

The effects of regulation and financial reform have transformed the nature of growth investing and significantly constrained access to the public markets for the fastest growing, most dynamic companies in the world.

In response to this reality, Healthios has created a new capital market system, dedicated to providing emerging growth companies with true public market alternative.

#RethinktheIPO

In 2016, Healthios launched the only unified Pre-IPO & IPO capital market dedicated exclusively to the emerging growth community.

  • CapBridge, Pte. ("CapBridge") provides pre-IPO financing for emerging growth companies with "post-money" valuations in excess of $70 million. CapBridge financings are subject to the receipt of a mandate letter relating to an IPO underwriting and the endorsement of the Singapore Stock Exchange ("SGX").
  • SGX Catalist provides IPO financing and liquidity solutions for emerging growth companies with target market capitalization between $100 and $350 million. SGX Catalist, a subsidiary of SGX, is a $7 billion public exchange dedicated exclusively to emerging growth companies.

Through CapBridge and Catalist, Healthios enables growth companies to access the public markets in a timely and cost effective manner which optimizes valuation and access to capital. For investors, Healthios' pre-IPO and IPO alternatives facilitate liquidity and ensure the best positioning from which to capitalize on further public listings along with "exit" and liquidity pathways.